Brain development in infants treated for retinopathy of prematurity (ROP) with anti-VEGF injection versus laser using data from term brain MRIs

Anti-VEGF agents have emerged as a valuable treatment for retinopathy of prematurity (ROP), especially in posterior type 1 disease. Though long-term safety in infants is largely unknown, growing evidence suggests anti-VEGF agents may effect newborn neuro-development. Intravitreal bevacizumab (IVB) is absorbed systemically and leads to suppression of serum VEGF for 2 weeks. Preterm infants treated with IVB vs laser had higher odds of...